MAGIC TRIAL 2006 NEMJ - ECF (Epirubicin, Cisplatin, 5FU) 3 x before and 3 x courses after surgery - Only 40% received post-op course - Increased R0 resection - 10% higher - Reduction in T stage and nodal status - Improved overall survival at 5 yrs – 36% vs 23% - Issues – Staging issues, R2 resection rate 32% vs 17%